Ondo has partnered with Chainlink to provide data support for over 100 tokenized stocks.

- Ethereum's 12% November price drop triggered strategic accumulation by institutions, with BitMine Immersion Technologies buying 3.5M ETH ($13.2B) to become the largest Ethereum treasury. - BitMine's "Alchemy of 5%" strategy aims to control 5% of Ethereum's supply, with recent $389M weekly purchases accelerating its 2.9% ownership stake. - Market reactions were mixed: Ethereum rebounded to $3,528 while exchange reserves hit 2016 lows, and BitMine's stock rose 5% despite 20% YTD losses. - Propanc Biopharma

- Greenidge Generation secured a 5-year air permit renewal in New York, resolving years of litigation and exceeding state climate goals with 44% emissions cuts. - The agreement boosted shares over 30% post-market, validating its hybrid power-crypto mining model while addressing regulatory uncertainty since 2022. - Despite $63M debt and negative EBITDA, the deal sets a crypto industry precedent with first-of-its-kind 25% actual emissions reductions in a Title V permit. - Greenidge plans to expand its modula

- U.S. Treasury and IRS issued guidance allowing crypto ETPs to stake Ethereum and Solana without regulatory risks, advancing PoS blockchain adoption. - Framework requires ETPs to hold single PoS assets, use qualified custodians, and maintain liquidity for redemptions during staking. - Staking yields (1.8-8% annually) now accessible to retail investors via compliant ETPs, with rewards taxed as income at receipt. - Industry leaders called the move transformative, removing legal barriers for fund sponsors wh

- SI-BONE reported Q3 2025 adjusted EBITDA of $2. 3M and raised full-year revenue guidance to $198M–$200M. - Gross margin expanded to 79.8%, while operating losses narrowed by 29.5% despite 11.9% higher operating expenses. - Cash reserves remained stable at $145.7M, with CEO citing growth from minimally invasive solutions and global expansion. - Analysts highlight innovation and expanded indications as key drivers for future orthopedic market share gains.